Pathology and pathobiology of pulmonary hypertension

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 551-559

  Guignabert, Christophe ^a,c   Dorfmuller, Peter ^a,b,c  

^a Universite Paris Sud   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

BMPR2; cellular cross talk; endothelial dysfunction; inflammation; pulmonary arterial hypertension; pulmonary vascular remodeling

Indexed keywords

ANGIOTENSIN II; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; CHEMOKINE RECEPTOR CX3CR1; FIBROBLAST GROWTH FACTOR 2; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHODIESTERASE V; PROSTACYCLIN; REACTIVE OXYGEN METABOLITE; SEROTONIN; SEROTONIN TRANSPORTER; TUMOR NECROSIS FACTOR ALPHA; VASOCONSTRICTOR AGENT; VOLTAGE GATED POTASSIUM CHANNEL;

ARTERIAL CIRCULATION; ARTERITIS; ARTICLE; AUTOIMMUNITY; BRONCHIAL ARTERY; CD4+ T LYMPHOCYTE; DEEP VEIN THROMBOSIS; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; GENE MUTATION; GENETIC ASSOCIATION; HYPERTROPHY; INFLAMMATION; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG BLOOD VESSEL; LUNG CIRCULATION; LUNG EMBOLISM; LUNG FIBROSIS; LUNG VASOCONSTRICTION; LYMPHOID TISSUE; MEDIAL HYPERTROPHY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY MALFORMATION; PULMONARY HYPERTENSION; PULMONARY VENO-OCCLUSIVE DISEASE; SCAR FORMATION; SENSITIVITY AND SPECIFICITY; SHEAR STRESS; SMOOTH MUSCLE FIBER; SYSTEMIC CIRCULATION; TUNICA MEDIA; VASCULAR NECROSIS; VASCULAR RESISTANCE; VASOSPASM;

ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FIBROSIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; LUNG; MUSCLE, SMOOTH, VASCULAR; PULMONARY ARTERY; PULMONARY CIRCULATION;

EID: 84884230238     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356496     Document Type: Article

References (79)

1. Humbert M., Morrell N. W., Archer S. L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol: 2004; 43 (12, Suppl S): 13S 24S
2. Morrell N. W., Adnot S., Archer S. L., et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S20 S31
3. Voelkel N. F., Gomez-Arroyo J., Abbate A., Bogaard H. J., Nicolls M. R. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J: 2012; 40 6 1555 1565
4. Eddahibi S., Guignabert C., Barlier-Mur A. M., et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. Circulation: 2006; 113 15 1857 1864
5. Xu R., Mao J. H. Gene transcriptional networks integrate microenvironmental signals in human breast cancer. Integr Biol (Camb): 2011; 3 4 368 374
6. Amabile N., Guignabert C., Montani D., Yeghiazarians Y., Boulanger C. M., Humbert M. Cellular microparticles in the pathogenesis of pulmonary hypertension. Eur Respir J: 2013; 42 1 272 279
7. Shimizu H., Tanabe N., Terada J., et al. Dilatation of bronchial arteries correlates with extent of central disease in patients with chronic thromboembolic pulmonary hypertension. Circ J: 2008; 72 7 1136 1141
8. Frazier A. A., Galvin J. R., Franks T. J., Rosado-De-Christenson M. L. From the archives of the AFIP: pulmonary vasculature: hypertension and infarction. Radiographics: 2000; 20 2 491 524, quiz 530-531, 532
9. Heath D., Williams D. High-Altitude Medicine and Pathology. London Butterworths: 1989
10. Sakao S., Tatsumi K., Voelkel N. F. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol: 2010; 43 6 629 634
11. Penaloza D., Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation: 2007; 115 9 1132 1146
12. Voelkel N. F., Tuder R. M. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J: 1995; 8 12 2129 2138
13. Cool C. D., Kennedy D., Voelkel N. F., Tuder R. M. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol: 1997; 28 4 434 442
14. Stacher E., Graham B. B., Hunt J. M., et al. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med: 2012; 186 3 261 272
15. Wagenvoort C., Wagenvoort N. Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases. Circulation: 1970; 42 1163 1184
16. Heath D., Edwards J. E. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation: 1958; 18 4 Part 1 533 547
17. Krowka M. J., Edwards W. D. A spectrum of pulmonary vascular pathology in portopulmonary hypertension. Liver Transpl: 2000; 6 2 241 242
18. Widgren S. [Prolonged survey of cases of pulmonary hypertension in relation to consumption of aminorex. Histological, quantitative and morphometric study of 9 cases]. Schweiz Med Wochenschr: 1986; 116 27-28 918 924
19. Tuder R. M., Abman S. H., Braun T., et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S3 S9
20. Moser K. M., Bloor C. M. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest: 1993; 103 3 685 692
21. Harrison C. V. IV. The pathology of the pulmonary vessels in pulmonary hypertension. Br J Radiol: 1958; 31 364 217 226
22. Piazza G., Goldhaber S. Z. Chronic thromboembolic pulmonary hypertension. N Engl J Med: 2011; 364 4 351 360
23. Kucsko L. [Arteriovenous communications in the human lung and their functional significance]. Frankf Z Pathol: 1953; 64 1 54 83
24. Saldaña M. E., Harley R. A., Liebow A. A., Carrington C. B. Experimental extreme pulmonary hypertension and vascular disease in relation to polycythemia. Am J Pathol: 1968; 52 5 935 981
25. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol: 1994; 144 2 275 285
26. Dorfmüller P., Perros F., Balabanian K., Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J: 2003; 22 2 358 363
27. Lee S. D., Shroyer K. R., Markham N. E., Cool C. D., Voelkel N. F., Tuder R. M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest: 1998; 101 5 927 934
28. Yaginuma G., Mohri H., Takahashi T. Distribution of arterial lesions and collateral pathways in the pulmonary hypertension of congenital heart disease: a computer aided reconstruction study. Thorax: 1990; 45 8 586 590
29. Cool C. D., Stewart J. S., Werahera P., et al. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol: 1999; 155 2 411 419
30. Dorfmüller P., Zarka V., Durand-Gasselin I., et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med: 2002; 165 4 534 539
31. Balabanian K., Foussat A., Dorfmüller P., et al. CX(3)C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med: 2002; 165 10 1419 1425
32. Sanchez O., Marcos E., Perros F., et al. Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med: 2007; 176 10 1041 1047
33. Dorfmüller P., Humbert M., Capron F., Müller K. M. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidosis Vasc Diffuse Lung Dis: 2003; 20 1 9 19
34. Perros F., Dorfmüller P., Souza R., et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J: 2007; 29 5 937 943
35. Perros F., Dorfmüller P., Montani D., et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med: 2012; 185 3 311 321
36. Carragher D. M., Rangel-Moreno J., Randall T. D. Ectopic lymphoid tissues and local immunity. Semin Immunol: 2008; 20 1 26 42
37. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol: 2006; 6 3 205 217
38. Hogg J. C., Chu F., Utokaparch S., et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med: 2004; 350 26 2645 2653
39. Rangel-Moreno J., Carragher D. M., de la Luz Garcia-Hernandez M., et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat Immunol: 2011; 12 7 639 646
40. Tamby M. C., Chanseaud Y., Humbert M., et al. Anti-endothelial cell antibodies in idiopathic and systemic sclerosis associated pulmonary arterial hypertension. Thorax: 2005; 60 9 765 772
41. Terrier B., Tamby M. C., Camoin L., et al. Identification of target antigens of antifibroblast antibodies in pulmonary arterial hypertension. Am J Respir Crit Care Med: 2008; 177 10 1128 1134
42. Dib H., Tamby M. C., Bussone G., et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J: 2012; 39 6 1405 1414
43. Dorfmüller P., Humbert M. Progress in pulmonary arterial hypertension pathology: relighting a torch inside the tunnel. Am J Respir Crit Care Med: 2012; 186 3 210 212
44. Price L. C., Wort S. J., Perros F., et al. Inflammation in pulmonary arterial hypertension. Chest: 2012; 141 1 210 221
45. Stevens T. Functional and molecular heterogeneity of pulmonary endothelial cells. Proc Am Thorac Soc: 2011; 8 6 453 457
46. Aird W. C. Endothelial cell heterogeneity. Crit Care Med: 2003; 31 (4, Suppl): S221 S230
47. Tuder R. M., Cool C. D., Yeager M., Taraseviciene-Stewart L., Bull T. M., Voelkel N. F. The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med: 2001; 22 3 405 418
48. Dinh-Xuan A. T. Endothelial modulation of pulmonary vascular tone. Eur Respir J: 1992; 5 6 757 762
49. Budhiraja R., Tuder R. M., Hassoun P. M. Endothelial dysfunction in pulmonary hypertension. Circulation: 2004; 109 2 159 165
50. Masri F. A., Xu W., Comhair S. A., et al. Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol: 2007; 293 3 L548 L554
51. Tu L., Dewachter L., Gore B., et al. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol: 2011; 45 2 311 322
52. Sakao S., Taraseviciene-Stewart L., Lee J. D., Wood K., Cool C. D., Voelkel N. F. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J: 2005; 19 9 1178 1180
53. Tu L., De Man F. S., Girerd B., et al. A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents. Am J Respir Crit Care Med: 2012; 186 7 666 676
54. Guignabert C., Alvira C. M., Alastalo T. P., et al. Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol: 2009; 297 6 L1082 L1090
55. Hong K. H., Lee Y. J., Lee E., et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation: 2008; 118 7 722 730
56. Guignabert C., Raffestin B., Benferhat R., Raoul W., Zadigue P., Rideau D., Hamon M., Adnot S., Eddahibi S. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation: 2005; 111 21 2812 2819
57. Izikki M., Guignabert C., Fadel E., Humbert M., Tu L., Zadigue P., Dartevelle P., Simonneau G., Adnot S., Maitre B., Raffestin B., Eddahibi S. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest: 2009; 119 3 512 523
58. de Man F. S., Tu L., Handoko M. L., Rain S., Ruiter G., François C., Schalij I., Dorfmüller P., Simonneau G., Fadel E., Perros F., Boonstra A., Postmus P. E., van der Velden J., Vonk-Noordegraaf A., Humbert M., Eddahibi S., Guignabert C. Dysregulated renin-angiotensin-aldosterone system contributes to pulmonary arterial hypertension. Am J Respir Crit Care Med: 2012; 186 8 780 789
59. Pengo V., Lensing A. WA, Prins M. H., et al. Thromboembolic Pulmonary Hypertension Study Group. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med: 2004; 350 22 2257 2264
60. Pietra G. G., Edwards W. D., Kay J. M., et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. Circulation: 1989; 80 5 1198 1206
61. Bjornsson J., Edwards W. D. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc: 1985; 60 1 16 25
62. Schermuly R. T., Ghofrani H. A., Wilkins M. R., Grimminger F. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol: 2011; 8 8 443 455
63. White R. J., Meoli D. F., Swarthout R. F., et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol: 2007; 293 3 L583 L590
64. Johnson S. R., Granton J. T., Mehta S. Thrombotic arteriopathy and anticoagulation in pulmonary hypertension. Chest: 2006; 130 2 545 552
65. Jouve P., Humbert M., Chauveheid M. P., Jaïs X., Papo T. POEMS syndrome-related pulmonary hypertension is steroid-responsive. Respir Med: 2007; 101 2 353 355
66. Montani D., Achouh L., Marcelin A. G., et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J: 2005; 26 5 969 972
67. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum: 2008; 58 2 521 531
68. Sanchez O., Sitbon O., Jaïs X., Simonneau G., Humbert M. Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest: 2006; 130 1 182 189
69. Launay D., Hachulla E., Hatron P. Y., Jais X., Simonneau G., Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore): 2007; 86 5 299 315
70. Tamby M. C., Humbert M., Guilpain P., et al. Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension. Eur Respir J: 2006; 28 4 799 807
71. Mouthon L., Guillevin L., Humbert M. Pulmonary arterial hypertension: an autoimmune disease? Eur Respir J: 2005; 26 6 986 988
72. Nicolls M. R., Taraseviciene-Stewart L., Rai P. R., Badesch D. B., Voelkel N. F. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J: 2005; 26 6 1110 1118
73. Huertas A., Tu L., Gambaryan N., et al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J: 2012; 40 4 895 904
74. Pietra G. G., Capron F., Stewart S., et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol: 2004; 43 (12, Suppl S): 25S 32S
75. Atkinson C., Stewart S., Upton P. D., et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation: 2002; 105 14 1672 1678
76. Teichert-Kuliszewska K., Kutryk M. J., Kuliszewski M. A., et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res: 2006; 98 2 209 217
77. Nasim M. T., Ogo T., Chowdhury H. M., et al. BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFβ-TAK1-MAPK pathways in PAH. Hum Mol Genet: 2012; 21 11 2548 2558
78. Yang X., Long L., Southwood M., et al. Dysfunctional Smad signaling contributes to abnormal smooth muscle cell proliferation in familial pulmonary arterial hypertension. Circ Res: 2005; 96 10 1053 1063
79. Germain M., Eyries M., Montani D., et al. Genome-wide association analysis identifies a susceptibility locus for pulmonary arterial hypertension. Nat Genet: 2013; 45 5 518 521